Olympus (TSE:7733) ROCE % : 17.16% (As of Sep. 2024)

View and export this data going back to 1949. Start your Free Trial

What is Olympus ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Olympus's annualized ROCE % for the quarter that ended in Sep. 2024 was 17.16%.

Olympus ROCE % Historical Data

The historical data trend for Olympus's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Olympus ROCE % Chart

Olympus Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

14.17

10.82

16.06

18.78

4.30

Olympus Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-5.90	12.22	1.92	10.40	17.16

Olympus ROCE % Calculation

Olympus's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	46160	/	( ( (1508701 - 461892)	+	(1534216 - 431695) )	/ 2 )
	=	46160	/	( (1046809	+	1102521)	/ 2 )
	=	46160	/	1074665
	=	4.30 %

Olympus's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	175348	/	( ( (1515386 - 419194)	+	(1366645 - 419575) )	/ 2 )
	=	175348	/	( ( 1096192	+	947070 )	/ 2 )
	=	175348	/	1021631
	=	17.16 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Olympus (TSE:7733) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Olympus ROCE % Related Terms

Thank you for viewing the detailed overview of Olympus's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Olympus Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Olympus Corp (TSE:7733) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

OLYMY:USA OCPNF:USA OLY1:Germany

Address

Shinjuku Monolith, 2-3-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, JPN, 163-0914

Website

http://www.olympus.co.jp

Olympus is a medical device maker with a leading position in the endoscope market and a diversified global revenue stream. Originally founded in 1919 in Japan as a microscope and camera maker, Olympus has gradually pivoted into endoscopic and therapeutic solutions. As of March 2024, more than 60% of its revenue comes from endoscopic solutions. In addition, North America is the biggest revenue contributor by region, accounting for 38% of its total revenue.

Olympus Headlines

No Headlines